The Double Marker Test is a vital prenatal screening conducted during the first trimester of pregnancy, typically between the 9th and 13th weeks. This blood test measures two key markers in the expectant mother’s blood — Free Beta-hCG and PAPP-A (Pregnancy-Associated Plasma Protein A) — to evaluate the risk of chromosomal abnormalities such as Down syndrome (Trisomy 21) and Edwards syndrome (Trisomy 18) in the developing fetus. Often recommended alongside a Nuchal Translucency (NT) scan, the Double Marker Test offers a more accurate early risk assessment. While it does not diagnose any condition directly, it helps doctors identify high-risk pregnancies that may require further confirmatory tests like NIPT or amniocentesis. Safe and non-invasive, this test plays a crucial role in ensuring informed prenatal care and helping expectant parents prepare confidently for a healthy pregnancy journey.